“Specialty Drugs”

45 result(s)
Cost Management
Strategies for managing drug spend for payors include helping members achieve better health and de-prescribing. More
Commentary
Cost Management
Payor strategies for specialty drug spend must strike a balance between affordability and member experience. More
Commentary
Drug Pipeline
Biosimilars help to increase market competition. Balancing the use of biosimilars and biologics with strategic formulary decisions deliver lower costs. More
Briefing
Care Management
Biogen’s new Alzheimer’s drug may be changing the treatment landscape, but lingering questions remain. More
Commentary
Specialty
Eliminating waste through Supply Management Optimization is important to effectively control spending on high-cost specialty medications. More
Briefing
Drug Pipeline
After many years of failure, there is hope for potential treatments that could slow disease progression for those with Alzheimer's Disease. If approved, Biogen's... More
Feature
Drug Pipeline
New drugs likely to offer patients more options. Key consideration for payors will be effectively balancing high — and rising — price tags with appropriate access. More
Feature
Drug Pipeline
CVS Health provides an early look at some key Breakthrough Therapies expected to be reviewed by the FDA in 2020 as well as the associated cost implications and expected approval... More
Feature
Drug Pipeline
New drugs to treat migraine are approaching approval and could bring relief for many patients, but they portend higher costs. Ongoing monitoring and appropriate utilization... More
Feature
Specialty
CVS Health is helping ensure a better member experience by simplifying the onboarding process and getting appropriate specialty therapies to members faster. More
Briefing